This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1ra5

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1ra5.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:1ra5.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1ra5| PDB=1ra5 | SCENE= }}
{{STRUCTURE_1ra5| PDB=1ra5 | SCENE= }}
-
'''Bacterial cytosine deaminase D314A mutant bound to 5-fluoro-4-(S)-hydroxyl-3,4-dihydropyrimidine.'''
+
===Bacterial cytosine deaminase D314A mutant bound to 5-fluoro-4-(S)-hydroxyl-3,4-dihydropyrimidine.===
-
==Overview==
+
<!--
-
Cytosine deaminase (CD) is currently being used as a suicide gene for cancer gene therapy. The premise of this therapy is the preferential deamination of 5-fluorocytosine (5FC) to 5-fluorouracil by cancer cells expressing cytosine deaminase. However, a lack of efficient gene transfer to tumors combined with inefficient 5FC turnover currently limits the clinical applications of this gene therapy approach. We have used random mutagenesis to create novel bacterial cytosine deaminases that demonstrate an increased preference for 5FC over cytosine. Among the 15 mutants isolated, one conferred sensitivity to Escherichia coli in a negative selection system at a concentration of 5FC that was 10-fold lower than a sublethal dose for wild-type CD. Evaluation of individual substitutions found in this double mutant (Q102R, D314G) demonstrated that the substitution at residue D314 was solely responsible for the observed increase in sensitivity to 5FC. Additional mutagenesis at D314 resulted in the identification of two more substitutions with the ability to confer enhanced 5FC sensitivity to E.coli. Structure determinations of the three CD variants in the presence and absence of a transition state 5FC analogue provide insights to the determinants of substrate binding specificity at the 5' position of the pyrimidine ring. CD mutant D314A is a promising candidate for further gene therapy studies.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15381761}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15381761 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15381761}}
==About this Structure==
==About this Structure==
Line 32: Line 36:
[[Category: D314a mutant]]
[[Category: D314a mutant]]
[[Category: Hexamer]]
[[Category: Hexamer]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 07:15:46 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 19:40:38 2008''

Revision as of 16:40, 28 July 2008

Image:1ra5.png

Template:STRUCTURE 1ra5

Bacterial cytosine deaminase D314A mutant bound to 5-fluoro-4-(S)-hydroxyl-3,4-dihydropyrimidine.

Template:ABSTRACT PUBMED 15381761

About this Structure

1RA5 is a Single protein structure of sequence from Escherichia coli. Full crystallographic information is available from OCA.

Reference

Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy., Mahan SD, Ireton GC, Knoeber C, Stoddard BL, Black ME, Protein Eng Des Sel. 2004 Aug;17(8):625-33. Epub 2004 Sep 20. PMID:15381761

Page seeded by OCA on Mon Jul 28 19:40:38 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1ra5"
Personal tools